Clinical Trials on Drug Metabolism, Poor, CYP2D6-RELATED in Russian Federation

Total 422 results

National Medical Research Center for Therapy and...
Center for Strategic Planning and Management of Biomedical Health Risks of...

Completed

Gut Microbiota in Chronic Noncommunicable Diseases

Diabetes Mellitus, Type 2 | Asthma | Nonalcoholic Fatty Liver Disease | Arterial Hypertension | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Obstructive Pulmonary Disease | Atherosclerosis Occlusive Disease

Russian Federation
Abbott Nutrition

Completed

Four-Hour Evaluation of a Medical Food in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2

Russian Federation
Sanofi

Completed

Evaluation of the Effectiveness and Safety of Physician Versus Patient-led of Insulin Glargine Initiation and Titration in Type 2 Diabetes Mellitus (ATLAS)

Diabetes Mellitus, Type 2

Japan, Russian Federation, China, India, Pakistan, Philippines
National Medical Research Center for Therapy and...

Recruiting

Middle-aged Women With Adverse Pregnancy Outcomes and Heart Failure With Preserved Ejection Fraction (MAPO-HF)

Pregnancy Complications | Heart Failure Preserved Ejection Fraction

Russian Federation
Saint Petersburg State University, Russia

Completed

Impact of Parathyroidectomy on Cardiovascular Calcification in Dialysis-dependent Patients

Secondary Hyperparathyroidism | Dialysis | Vascular Calcification | Chronic Kidney Disease Mineral and Bone Disorder

Russian Federation
Geropharm

Completed

Efficacy and Safety of Insulin RinGlar® Compared to Lantus® SoloStar® in Type 1 Diabetes Mellitus Patients

Diabetes Mellitus | Diabetes Mellitus, Type 1

Russian Federation
SatRx LLC

Completed

Efficacy and Safety of Gosogliptin as Monotherapy and in Combination With Metformin vs. Vildagliptin as Monotherapy and in Combination With Metformin in Drug-naive Type 2 Diabetic Patients.

Diabetes Mellitus, Type 2

Russian Federation
Novo Nordisk A/S

Completed

Effect of Biphasic Insulin Aspart 30 on Blood Glucose Control in Subjects With Type 2 Diabetes

Diabetes Mellitus, Type 2 | Diabetes

Russian Federation
Geropharm

Completed

Efficacy and Safety of Insulin Lispro Biphasic 25 Compared to Humalog® Mix 25 in Type 2 Diabetes Mellitus Patients

Diabetes Mellitus, Type 2 | Diabetes Mellitus

Russian Federation
Sanofi

Completed

Tulip Study: Testing the Usefulness of Lantus When Initiated Prematurely In Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

France, Russian Federation, Croatia, Slovenia, Czech Republic, Romania
Central Clinical Hospital w/Outpatient Health Center...

Unknown

Effectiveness and Safety of Adipose-Derived Regenerative Cells for the Treatment of Critical Lower Limb Ischemia

Diabetic Angiopathies | Peripheral Arterial Disease | Critical Limb Ischemia | Thromboangiitis Obliterans | Arteriosclerosis Obliterans

Russian Federation
Federal State Budgetary Institution, V. A. Almazov...
Russian Cardiology Research and Production Center; National Research Center...

Unknown

Cardiovascular Epidemiology in Russian Federation (ESSE-RF)

Coronary Artery Disease | Heart Failure | Smoking | Hypertension | Diabetes | Lifestyle

Russian Federation
Geropharm

Completed

Efficacy and Safety of GP40071 Compared to NovoRapid® Penfill® in Type 1 Diabetes Mellitus Patients

Diabetes | Diabetes Mellitus, Type 1

Russian Federation
Biotec Pharmacon ASA

Completed

Efficacy of Soluble Beta-1,3/1,6-Glucan Compared to Placebo on Chronic Leg Ulcers in Diabetes Patients

Foot Ulcer

Russian Federation
Eurasian Association of Therapists

Completed

Analysis of Health Status of Сomorbid Adult COVID-19 Patients Hospitalised in Second Wave of SARS-CoV-2 Infection (ACTIV-2)

Diabetes | Covid19 | Death | Atrial Fibrillation | Risk Factor, Cardiovascular | CKD | COPD | Comorbidities and Coexisting Conditions | DVT

Russian Federation
Tyumen State Medical Academy

Unknown

Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants

Hyperandrogenism | Polycystic Ovarian Syndrome | Menstrual Irregularities

Russian Federation
Materia Medica Holding

Completed

Clinical Trial of Efficacy and Safety of Subetta in the Combined Treatment of Patients With Type I Diabetes Mellitus

Type I Diabetes Mellitus

Russian Federation
MEDA Pharma GmbH & Co. KG

Completed

Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2)

Diabetic Polyneuropathy

Israel, Russian Federation
Sanofi

Completed

Efficacy and Safety of the Fixed Dose Combination of Glimepiride+Metformin in Type 2 Diabetic Patients Inadequately Controlled (LEGEND)

Type 2 Diabetes Mellitus

Lebanon, Russian Federation, Ukraine
Eurasian Association of Therapists

Completed

Analysis of Chronic Non-infectious Diseases Dynamics After COVID-19 Infection in Adult Patients (ACTIV)

Cardiovascular Diseases | Pneumonia | Hypertension | Diabetes | Covid19 | Coronary Heart Disease | Copd | CKD | Overweight and Obesity | SARS-CoV-2 Infection | Cardiac Event

Russian Federation
Novo Nordisk A/S

Completed

Examining the Long-term Safety of Insulin Aspart When Used as a Part of the Treatment for Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Russian Federation, Israel, Croatia, Czech Republic, Slovenia
Eurasian Association of Therapists

Recruiting

Real Clinical Practice Register of AlbUminuRia Detection in Patients With Previously undiAgnosed Chronic Kidney Disease (AURA)

COVID-19 | Hypertension | Cancer | Chronic Kidney Diseases | Chronic Obstructive Pulmonary Disease | Atrial Fibrillation | PreDiabetes | Ischemic Heart Disease | Chronic Heart Failure | Urolithiasis

Russian Federation
Materia Medica Holding

Completed

Clinical Trial of Efficacy and Safety of Subetta in the Combined Treatment of Patients With Type II Diabetes Mellitus

Type II Diabetes Mellitus

Russian Federation
Novo Nordisk A/S

Completed

Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes

Diabetes | Diabetes Mellitus, Type 1

Germany, South Africa, Russian Federation, Former Serbia and Montenegro, North Macedonia
Bayer

Completed

GlucoVIP - Diabetes Treatment by Glucobay® With a Special Therapeutic View to Chosen Patient Groups

Diabetes Mellitus

Russian Federation, India, Korea, Republic of, Indonesia, Malaysia, Philippines, Singapore, Thailand, China, Hong Kong, Pakistan, Vietnam, Algeria, Moldova, Republic of, Bosnia and Herzegovina, Cambodia
Sanofi

Completed

Dose Ranging Study of the GLP-1 Agonist AVE0010 in Metformin-Treated Subjects With Type 2 Diabetes Mellitus

Type 2 Diabetes

United States, Canada, Brazil, Poland, Romania, Russian Federation, Ukraine
Mannkind Corporation

Completed

Comparison Between Technosphere/Insulin Inhalation Powder Versus Rapid Acting Insulin in Subjects With Type 2 Diabetes Mellitus

Diabetes Type 2

Russian Federation
Bristol-Myers Squibb

Completed

Proof of Confidence Study of CCR2 Antagonist (BMS-741672) in Insulin Resistance

Type 2 Diabetes

Russian Federation
Eurasian Association of Therapists

Completed

Analysis of Health Status of Сomorbid Adult Patients With COVID-19 Hospitalised in Fourth Wave of SARS-CoV-2 Infection (ACTIV4)

Myocardial Infarction | Stroke | COVID-19 | Diabetes Mellitus | Chronic Kidney Diseases | Ischemic Stroke | Anemia | Atrial Fibrillation | Asthma | Myocarditis | Ischemic Heart Disease | Chronic Heart Failure | Copd | Overweight and Obesity | Pulmonary Embolism | Oncology | Arrythmia | DVT | Hypertensive Heart Disease

Russian Federation
Charite University, Berlin, Germany
University of Hull; IRCCS San Raffaele; Hannover Medical School; Russian Cardiology... and other collaborators

Completed

Studies Investigating Co-morbidities Aggravating Heart Failure (SICA-HF)

Heart Failure | Type 2 Diabetes Mellitus

Germany, Slovenia, United Kingdom, Italy, Poland, Russian Federation
Novo Nordisk A/S

Completed

Observational Study of Safety and Effectiveness of NovoMix® 30 for the Treatment of Diabetes (IMPROVE™)

Diabetes Mellitus, Type 2 | Diabetes

Saudi Arabia, China, India, Iran, Islamic Republic of, Korea, Republic of, Russian Federation, Poland, Japan, Italy, Canada, Greece
Novartis

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Type 2 Diabetes

Type 2 Diabetes Mellitus

Russian Federation, Germany, United States
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy (GETGOAL-MONO)

Diabetes Mellitus, Type 2

United States, Poland, Romania, Russian Federation, Ukraine, India, Belgium, Mexico, Tunisia, Japan, Israel, Korea, Republic of
Sanofi

Terminated

Effect of Rimonabant and Metformin Combination on Glycemic Control in Patients With Type 2 Diabetes (TOCCATA)

Diabetes Mellitus, Type 2

United States, Poland, Romania, Russian Federation, Ukraine, Malaysia, Philippines, Taiwan, Mexico, Lithuania, Slovakia, Indonesia, Thailand
Eli Lilly and Company

Terminated

A Study of LY2599506 (Oral Agent Medication: Glucokinase Activator 1) in Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

Russian Federation, Spain, Germany, Australia, Austria, Israel, Czech Republic
AstraZeneca
Bristol-Myers Squibb

Completed

Screening Epidemiological Program on Compensation Evaluation of Diabetes Mellitus Type 2 (DMT2) Patients on Oral Anti-diabetic (OAD) Monotherapy and Physicians Satisfaction of Their Usage

Type 2 Diabetes

Russian Federation
POLYSAN Scientific & Technological Pharmaceutical...

Completed

Cytoflavin in the Treatment of Patients With Diabetic Polyneuropathy (CYLINDER)

Diabetic Neuropathies

Russian Federation
Sanofi

Completed

Study Evaluating Rimonabant Efficacy in Insulin-Treated Diabetic Patients(ARPEGGIO)

Type 2 Diabetes Mellitus

France, Russian Federation, United States, Argentina, Canada, Germany, South Africa, Italy, Netherlands, United Kingdom, Australia, Chile
Novo Nordisk A/S

Completed

GAPP 1 Survey: Global Attitudes of Patients and Physicians in Insulin Therapy for Diabetes Mellitus

Diabetes Mellitus, Type 2 | Diabetes | Diabetes Mellitus, Type 1

Spain, China, India, Russian Federation, Turkey, Germany, Japan, United Kingdom, France, United States
Sanofi

Terminated

A Glycemic Control Evaluation of Glimepiride Versus Rimonabant on Top of Metformin in Type 2 Diabetes (ALLEGRO)

Diabetes Mellitus, Type 2

United States, Romania, Russian Federation, Spain, Sweden, India, Mexico, Denmark, Finland, Hungary, Italy, Korea, Republic of, Chile, Puerto Rico
Takeda

Completed

An Observational Study of Alogliptin Benzoate in Participants With Diabetes Mellitus Type 2

Diabetes Mellitus

Russian Federation
Sanofi

Completed

Opposing Step-by-step Insulin Reinforcement to Intensified Strategy (OSIRIS)

Diabetes Mellitus, Type 2

France, Korea, Republic of, Russian Federation, Spain, Italy, Belgium, Germany, Hungary, Ireland, Mexico, Poland, Taiwan, Turkey, Netherlands, Greece, Lithuania, Sweden, United Kingdom
Novartis

Completed

Safety and Tolerability of Vildagliptin Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency

Diabetes Mellitus, Type 2

Spain, Argentina, Russian Federation, Norway, India, Sweden, Finland, France, Canada, Germany, Australia, Costa Rica
Boehringer Ingelheim
Eli Lilly and Company

Completed

Finding a Safe and Effective Dose of Linagliptin in Pediatric Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Canada, France, Guatemala, Italy, Korea, Republic of, Mexico, Poland, Russian Federation
AstraZeneca

Completed

Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Saxagliptin as Monotherapy in Pediatric Patients With Type 2 Diabetes

Type 2 Diabetes

United States, Russian Federation, South Africa, Taiwan
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin (GETGOAL-L)

Diabetes Mellitus, Type 2

United States, France, Canada, Brazil, Russian Federation, Germany, Italy, Turkey, India, Mexico, Egypt, United Kingdom, Korea, Republic of, Chile, Puerto Rico
Ionis Pharmaceuticals, Inc.

Completed

Placebo Controlled, Dose Escalation Study in Subjects With Type 2 Diabetes Mellitus Being Treated With Sulfonylurea

Type 2 Diabetes Mellitus

Poland, Romania, Russian Federation
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin (GETGOAL-M)

Diabetes Mellitus, Type 2

United States, Canada, Romania, Russian Federation, Ukraine, Germany, Spain, Philippines, Czech Republic, Mexico, Croatia, Chile, Morocco, South Africa, Australia, Venezuela
Sanofi

Completed

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Sulfonylurea (GETGOAL-S)

Diabetes Mellitus, Type 2

United States, Romania, Russian Federation, Germany, Netherlands, Turkey, Bulgaria, India, Taiwan, Czech Republic, Tunisia, Japan, Egypt, Israel, Korea, Republic of, Thailand
AstraZeneca
Eli Lilly and Company

Completed

Safety and Efficacy of Exenatide as Monotherapy

Type 2 Diabetes Mellitus

Russian Federation, Romania, United States, India, Puerto Rico

Clinical Trials on Drug Metabolism, Poor, CYP2D6-RELATED in Russian Federation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Papua New Guinea

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations